US Stock MarketDetailed Quotes

CMMB Chemomab Therapeutics

Watchlist
  • 2.010
  • +0.020+1.01%
Close Dec 27 16:00 ET
  • 1.960
  • -0.050-2.49%
Post 20:01 ET
37.90MMarket Cap-2.14P/E (TTM)

Chemomab Therapeutics Key Stats

Chemomab Therapeutics Q3 2024 Earnings Date

Currency:USDNov 14, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
EPS
-<0.01
-0.20
-0.19
Miss Est.
+41.42%
+41.18%
-1920.20%
Net Income
--
-3.48M
--
+14.65%
Strong Buy

Nov 30, 2024

Chemomab Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 14, 20242024/Q30.000 / 0.000--
Aug 21, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 14, 20242024/Q30.000 / 0.000--
Aug 21, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Chemomab Therapeutics Earnings Reports

Read more

Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Nov 30, 2024

Strong Buy

  • Buy

    100.00%
  • Hold

    0.00%
  • Sell

    0.00%

Price Target

No Data